Key result
Three small molecules directly bind β-arrestins and disrupt GPCR engagement, providing new therapeutic tools.
Why the study?
Small molecules binding directly to β-arrestins to inhibit their activities were needed as chemical tools to probe their biology and open avenues for transducer-targeted, pathway-specific GPCR therapeutics.
The identification of the first chemical inhibitors of β-arrestins provides novel tools to probe GPCR biology and develop pathway-specific therapeutics.
Enables targeted GPCR research; leaves open clinical translation to pathway-specific therapies.
Proteins called β-arrestins regulate signalling through members of the G protein-coupled receptor (GPCR) superfamily. Small molecules that bind directly to the β-arrestins and inhibit their activities are the first chemical tools to probe their biology, opening avenues for transducer-targeted, pathway-specific GPCR therapeutics. Three small molecules disrupt the engagement of β-arrestins with G-protein-coupled receptor proteins.
No takes yet. Share an insight, caveat, or question.
A 2026 study studied this question. Small molecule inhibitors of β-arrestin proteins was evaluated on Disruption of engagement of β-arrestins with G-protein-coupled receptor proteins. Three small molecules were identified that bind directly to β-arrestins and disrupt their engagement with G-protein-coupled receptor proteins, providing new chemical tools for GPCR therapeutics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: